1. Back to the Basics of Dyslipidemia

3. Background

4. Background (cont)

5. Pathophysiology of the Coronary Artery Athero-Inflammatory-Thrombotic Process

6. Potential Beneficial Effects of EPA on Clinical CV Endpoints

8. Cellular and Molecular Mechanisms of Atherosclerosis

9. Integrated Perspective on CV Risk Factors and Atherosclerosis

10. LDL Oxidation Leads to Plaque Instability and Reduced Rates of Clearance

11. Proposed Mechanisms for the Atherogenicity of TG-Rich Lipoproteins

12. Effects of Omega-3 (EPA) Fatty Acids on Membranes

13. Comparative Effects of EPA, Fenofibrate, Niacin, Gemfibrozil, and Vitamin E on Human Small Dense LDL Oxidation

14. EPA Inhibits Human sdLDL Oxidation In Vitro as Compared to DHA Over Time

15. Effects of EPA vs Other TG-lowering Agents

16. Treatment Considerations

17. Statins

18. Combined Effects of EPA and Atorvastatin on Human Endothelial Function after Treatment With Oxidized LDL

19. Factors Contributing to Cardiometabolic Risk

20. Role of Insulin Resistance and Compensatory Hyperinsulinemia

21. Metabolic Syndrome What Can We Do About It?

22. Treatment Options for Metabolic Syndrome

23. EPA + DHA and Lipid Levels in Patients With TG > 500 mg/dL

24. The MARINE Study

25. ANCHOR Study: EPA + Statin vs Statin Alone EPA and Lipid Endpoints

26. Potential Beneficial Effects of EPA on Clinical CV Endpoints

27. Advantages of EPA Compared With DHA

28. Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

29. JELIS EPA Reduced Major Coronary Events
JELIS EPA Reduced Major Coronary Events* in Hypercholesterolemic Patients on Statins

30. JELIS

31. EPA Effects

32. Biologic Plausibility, Vascular/Endothelial Function Effects, and Clinical Outcomes Associated With Commonly Used TG-Lowering Medications

33. GISSI vs JELIS (Omega-3 Outcomes Studies)

34. Prescription EPA-Only vs Omega-3 Dietary Supplements

35. Prescription EPA-Only vs Omega-3 Dietary Supplements (cont)

36. REDUCE-IT Reduction of Cardiovascular Events With EPA -- Intervention Trial

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)